Table 1.

Hospital-level inotrope use rates, stratified by quartiles of risk-standardized hospital rates of inotrope use.

Variable	Overall	Q1	Q2	Q3	Q4
		Low Use Hospitals			High Use Hospitals
		N=52	N=52	N=53	N=52
Inotrope use, OBSERVED, at the hospital level
Overall:
median	3.9%	1.0 %	2.7%	4.7%	10.4%
IQR	1.8–7.2%	0.0–1.9%	1.6–4.0%	3.2–6.9%	7.1–15.4%
Range	0.0–34.4%	0.0–8.4%	0.0–7.5%	1.7–22.1%	3.6–34.4%
Dopamine:
median	1.5%	0.6%	1.2%	2.2%	2.9%
IQR	0.6–2.7%	0.0–1.1%	0.1–1.8%	1.1–3.6%	1.9–4.8%
Range	0.0–27.9%	0.0–2.4%	0.0–3.9%	0.0–7.4%	0.0–27.9%
Dobutamine:
median	1.9%	0.4%	1.4%	2.4%	5.5%
IQR	0.6–4.0%	0.0–0.8%	0.6–2.3%	1.0–3.8%	3.3–10.0%
Range	0.0–28.1%	0.0–3.9%	0.0–5.6%	0.0–15.2%	0.8–28.1%
Milrinone:
median	0%	0%	0%	0.5%	1.0%
IQR	0.0–1.0%	0.0–0.2%	0.0–0.5%	0.0–1.2%	0.0–2.8%
Range	0.0–21.7%	0.0–5.3%	0.0–3.5%	0.0–11.3	0.0–21.7%
Inotrope use, RISK-STANDARDIZED for patient and hospital factors, at the hospital level
Overall:
median	5.9%	3.1%	4.7%	7.0%	11.5%
IQR	3.7–8.6%	2.3–3.5%	4.1–5.3%	6.6–7.8%	9.8–18.5%
Range	1.3–32.9%	1.3–3.7%	3.7–5.8%	5.9–8.6%	8.6–32.9%

Q=quartile; IQR=interquartile range.